Trials / Completed
CompletedNCT00191971
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
A Phase II Study of Gemcitabine in Transitional Cell Carcinoma of the Urothelium
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine |
Timeline
- Start date
- 2004-01-01
- Completion
- 2006-09-01
- First posted
- 2005-09-19
- Last updated
- 2007-11-06
Locations
12 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00191971. Inclusion in this directory is not an endorsement.